CRMD - CIK 0001410098
CorMedix Inc. trades as CRMD. In its fiscal 2025 annual report the company posted revenue of $311.71M, up 617.0% from the prior year and net income of $163.06M. This page tracks CorMedix Inc. through 1,001 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 10 fiscal years CorMedix Inc.'s revenue grew from $210.13K to $311.71M, a compound annual growth rate of 107.6%. Net profit margin expanded from -10996.5% to 52.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
| Major company event | 8-K | 2026-04-27 |
| PRE 14A | - | 2026-04-17 |
The largest companies sharing CorMedix Inc.'s SEC industry classification (pharmaceutical preparations).
CorMedix Inc. reported revenue of $311.71M for fiscal year 2025, an increase of 617.0% year over year.
Yes. CorMedix Inc. reported net income of $163.06M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.